ATLANTA and CAMBRIDGE, Massachusetts, Aug. 13, 2015 /PRNewswire/ -- Inhibikase Therapeutics, Inc. announces the launch of an observational clinical study in patients who contracted Progressive Multifocal Leukoencephalopathy (PML), the rare and often fatal brain infection that arises as an unintended side effect of some medications used for treatment of Multiple Sclerosis, Crohn's disease, Ulcerative Colitis and certain cancers of the blood and lymph. PML also arises in patients with HIV/AIDS.

"The study intends to establish a link between the Company's proprietary measures of JCV viral load and PML cases," said Inhibikase CEO Dr. Milton Werner. "PML is induced by medications that mobilize a virus, JCV, to escape from its reservoir in the kidney and migrate into the brain. Once in the brain, JCV causes irreversible damage, often leading to death. The Company has a robust method for measurement of viral load in living patients. We now wish to measure the relationship between JCV viral load and JCV antibody titer in patients who survived the acute phase of the infection. PML survivors are a treasure trove of information that can help us to better understand the natural history and clinical virology of the disease. This is an important lead-up to the advancement of the Company's lead antiviral, IKT-001Pro, into clinical development, which initiates in the 3^rd or 4^th quarter of 2015."

"Because PML is such a rare disease, patients who survive the acute phase of the infection are very difficult to identify," noted Dr. Werner. "Only a few hundred such patients reside in the U.S. or Europe, so the Company sought and received approval from its Advisory Board, as well as a national Institutional Review Board (IRB), to reach out to patients directly through the online, social and print media. To date, 12 such patients have contacted the Company to learn about the study. We urge any patients who survived PML to contact the Company through its secure email service at PMLSurvivor@inhibikase.com or to visit Inhibikase.com for further information."

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases. Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action. The Company's host-targeting strategy using clinically validated targets treat infectious disease with a low likelihood of stimulating resistance. Founded in 2008 and headquartered in Atlanta, Georgia with offices in Cambridge, Massachusetts, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML), BK-virus associated nephropathy (PVAN), fungal and bacterial pneumonias as well as medical countermeasures for biodefense. Its RAMP technology is developing next generation small molecule inhibitors suitable for treatment of infections and certain cancers using single agents at a fixed dose.

Contact:
Milton H. Werner, Ph.D.
President & CEO
Inhibikase Therapeutics, Inc.
(917) 494-0831

Related Links

http://www.inhibikase.com

SOURCE Inhibikase Therapeutics, Inc.